MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination – ILCN.org (ILCN/WCLC)
Compared to chemotherapy alone, the addition of the EGFR-MET bispecific antibody significantly prolonged progression-free survival after subsequent therapy, said Dr. Ryan Gentzler during the European Lung Cancer Congress.